Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, October 26, 2021
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
[ Tue, Oct 26th 2021
] - WOPRAI
Mon, October 25, 2021
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
[ Mon, Oct 25th 2021
] - WOPRAI
Raghuram Selvaraju Maintained (BBIO) at Strong Buy with Increased Target to $88 on, Oct 25th, 2021
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Increased Target from $87 to $88 on, Oct 25th, 2021.
Raghuram has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $68 on, Monday, October 4th, 2021
- Geoff Meacham of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $75 on, Friday, September 10th, 2021
